SipNose’s devices enable precise delivery of systemic, local and direct-to-brain therapies. Credit: New Africa/Shutterstock.

Aptar Pharma, a provider of drug delivery systems, has acquired all device technology assets from SipNose Nasal Delivery Systems’ portfolio, expanding its presence in the intranasal drug delivery market.

This strategic move will enhance Aptar Pharma’s patent product portfolio and support the development of new products.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

SipNose’s diverse range of devices are designed to target specific areas within the nasal cavity.

These devices enable precise delivery of local, systemic and direct-to-brain applications, which is crucial for a variety of therapies.

Aptar Pharma Prescription president Alex Theodorakis said: “Our nasal systems’ proven capabilities have brought added value to our customers and further convenience for patients worldwide for over 30 years.

See Also:

“As the nasal market looks to develop new drugs to address unmet patient needs, this transaction will enhance Aptar’s portfolio of nasal drug delivery systems with a focus on CNS [central nervous system] diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition of SipNose’s delivery systems including liquid and dry powder intranasal technologies is expected to enhance Aptar Pharma’s expertise in the nose-to-brain pathway.

This will facilitate further development and scientific research within the sector.

Aptar Pharma business development director Reenal Gandhi said: “SipNose is focused on development and innovation in intranasal drug delivery. Integrating these assets into our portfolio underlines Aptar Pharma’s continued expansion into the nasal drug delivery space.”

Founded in 2011, SipNose is focused on the development of nasal drug delivery solutions by combining technological and engineering expertise with medical and scientific knowledge.

Last month, Aptar Digital Health joined forces with Guy’s and St Thomas’ NHS Foundation Trust in the UK to assess the impact of its digital Respiratory Disease Management Platform on asthma patients in a trial.